Cardinal Health Inc (CAH) · Nov 5, 2026 · Earnings
Beat — Non-GAAP EPS $3.26 vs ~$2.95 consensus
Cardinal Health’s Q1 earnings beat published expectations and lifted FY27 EPS guidance, though its medical distribution turnaround remains uneven.
Cardinal Health is still being driven by its Pharmaceutical and Specialty Solutions business, while it works through a multi-year improvement plan in Global Medical Products and Distribution (GMPD). Its fiscal 2026 strategy emphasized specialty growth, expansion of smaller growth businesses, and GMPD operational simplification and cost reduction.
The quarter beat the published bar and raised the full-year outlook. Non-GAAP diluted EPS reached $3.26 versus published consensus of roughly $2.95, while revenue was $67.5 billion versus about $66.6 billion expected. The more important change is forward-looking: management lifted FY27 non-GAAP EPS guidance to $12.80–$13.00 from $12.40–$12.60.
| Figure | Q1 FY27 | Q1 FY26 | Consensus / prior guide |
|---|---|---|---|
| Non-GAAP diluted EPS (Financial Highlights) | $3.26 (+28%) | $2.55 | $2.95 consensus |
| Revenue (Financial Highlights) | $67.5B (+5%) | $64.0B | $66.6B consensus |
| Pharmaceutical & Specialty Solutions profit (Segment results) | $783M (+17%) | $667M | |
| GMPD segment profit (Segment results) | $33M (-28%) | $46M | |
| FY27 non-GAAP EPS outlook (Guidance) | $12.80–$13.00 | $12.40–$12.60 prior guide |
The core earnings engine is outperforming, not merely benefiting from accounting noise. Pharmaceutical and Specialty Solutions profit rose 17%, helped by branded and specialty products and the generics program, while consolidated non-GAAP operating earnings increased 17% to $1.0 billion.
GMPD remains the clear weak spot. Revenue was roughly flat and segment profit fell 28% to $33 million because of unfavorable distribution and foreign-exchange impacts. That does not overturn the broader result, but it shows the turnaround is still incomplete and leaves less room for execution misses in the medical-products business.
The CVS renewal is important strategically but not fresh news today. Cardinal Health had already disclosed the binding letter of intent in October, including continuation of the relationship through June 2032, so this filing mainly confirms the agreement while the earnings and guidance raise provide the new information. 〔0〕
Bottom line: This is a clearly stronger-than-expected start to FY27, with the main growth engine delivering enough upside to lift the full-year target. GMPD is still under pressure, but its weakness is outweighed by the earnings beat and raised outlook.
Q2 FY27 earnings report
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!